https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43676 Wed 28 Sep 2022 08:09:49 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52945 Wed 28 Feb 2024 16:18:26 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51393 Wed 28 Feb 2024 16:04:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52294 Wed 28 Feb 2024 15:42:27 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53434 Wed 28 Feb 2024 15:37:47 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53993 Wed 28 Feb 2024 15:26:38 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39526 Wed 27 Jul 2022 14:04:52 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45043 n = 717) were administered the Structured Clinical Interview for DSM-IV (SCID-I/NP and SCID-II) and the World Health Organisation Quality of Life scale (WHOQOL-BREF). Weight and height were measured and lifestyle and demographic factors were self-reported. Logistic regression models (odds ratios with 95% confidence intervals) were undertaken to investigate associations among groups (mental state disorders, co-occurring mental state disorders with PD, and controls) and the WHOQOL-BREF domains (physical, psychological, social, and environmental health) while testing for potential confounding. Results: Results indicated that mental state disorders were associated with increased risk of low quality of life in physical, psychological, social, but not environmental domains, compared to controls. This risk was increased among women with co-occurring PD across all domains compared to both controls and those with mental state disorders. Conclusion: These findings add evidence suggesting poor quality of life is experienced by those with mental state disorders, and that this is worsened by the experience of co-occurring PD.]]> Wed 26 Oct 2022 12:00:30 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35721 Wed 24 May 2023 12:21:56 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51394 Wed 24 Apr 2024 12:04:11 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38853 r = 0.3–0.5; P ≤ 0.05). Total ARCS predicts cognitive impairment with good sensitivity and specificity relative to the BICAMS tests (AUC = 0.8; P = 0.00045). Total ARCS detects higher levels of impairment than BICAMS in MS patients (44% versus 21%). The memory domain of the ARCS and the BVMT-R were the best predictors of employment status (OR = 1.12 and 1.14, P  < 0.05). Conclusion: BICAMS and ARCS have comparable sensitivity for cognitive impairment in MS. Memory assessment from either tests is the best predictor of employment status; however, the BICAMS is a better predictor of work productivity.]]> Wed 23 Nov 2022 15:41:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44652 Wed 19 Oct 2022 09:49:35 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35082 Wed 19 Jun 2019 17:05:48 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48370 Wed 15 Mar 2023 13:19:49 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48019 Wed 15 Feb 2023 10:48:01 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48056 Wed 13 Mar 2024 14:24:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54400 Wed 13 Mar 2024 14:18:27 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47988 Wed 13 Mar 2024 07:50:20 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37829 Wed 12 May 2021 10:14:39 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35856 Wed 11 Dec 2019 14:51:22 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53707 Wed 10 Jan 2024 11:03:19 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36821 Wed 08 Jul 2020 13:55:42 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48384 Wed 06 Mar 2024 14:43:48 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50154 Wed 05 Jul 2023 14:26:05 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38160 0.05), and the intervention significantly improved the ASI (all p < 0.05). A more favourable ASI score was associated with improved symptoms of depression, anxiety, stress, QOL-mental and of energy and fatigue (all p < 0.05). The intervention effects on symptoms of depression ([AB; 95%CI] -0.31; - 0.60,-0.11), anxiety (- 0.11; - 0.27,-0.01), stress (- 0.37; - 0.65,-0.174), QOL-mental (0.53; 0.22, 1.01) and ratings of energy and fatigue (0.85; 0.33, 1.63) were mediated by ASI. At 6 months the magnitude of association was larger although the overall pattern of results remained similar. Conclusions: Improvements in the overall physical activity and sleep behaviours of adults partially mediated the intervention effects on mental health and quality of life outcomes. This highlights the potential benefit of improving the overall pattern of physical activity and sleep on these outcomes. Trial registration: Australian New Zealand Clinical Trial Registry: ACTRN12617000680369; ACTRN12617000376347. Universal Trial number: U1111–1194-2680; U1111–1186-6588. Human Research Ethics Committee Approval: H-2016- 0267; H-2016–0181.]]> Wed 04 Aug 2021 18:44:37 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38127 Wed 04 Aug 2021 15:07:37 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52864 Wed 03 Apr 2024 15:29:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45582 p = 0.002), cognitive functioning (45 vs 19%: p = 0.021), fatigue (47 vs 19%: p = 0.015) and global health status (42 vs 9%: p = 0.003). Conclusion: Although the objective response rate to anastrozole was relatively low, clinical benefit was observed in 44% of patients with ER/PR positive metastatic endometrial cancer and associated with an improvement in QOL.]]> Wed 02 Nov 2022 10:37:04 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55237 Wed 01 May 2024 15:42:40 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54058 Tue 30 Jan 2024 13:55:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37078 Tue 29 Sep 2020 11:48:51 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46686 Tue 29 Nov 2022 09:36:12 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48620 Tue 28 Mar 2023 10:04:21 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48110 Tue 28 Feb 2023 15:58:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43522 10) (OR = 2.83, 95% CI: 0.94–8.11, p = 0.047), being overweight (≥25 kg/m2) (OR = 2.57, 95% CI: 1.04 – 6.38, p = 0.036), received fewer post-surgery rehabilitation treatment (OR = 2.37, 95% CI: 1.05–5.39, p = 0.036) and hypertension (OR = 2.38, 95% CI: 1.01–5.62, p = 0.043 ) were associated with an increased risk of BCRL. Meanwhile, multivariate analysis showed that multiple surgeries remained significant and elevated the likelihood of BCRL (OR = 5.83, 95% CI: 1.14–29.78, p = 0.034). Arm swelling was more prominent in the forearm area demonstrated by the highest difference of arm circumference measurement when compared to the upper arm ( 2.07 ± 2.48 vs. 1.34 ± 1.91 cm, p < 0.001). The total of skinfold thickness of the affected forearm was also significantly higher than the unaffected arms (p < 0.05) as evidenced by the ultrasound examination. The continuous search for risk factors in specific populations may facilitate the development of a standardized method to reduce the occurrence of BCRL and provide better management for breast cancer patients.]]> Tue 27 Jun 2023 09:47:57 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54548 Tue 27 Feb 2024 20:42:16 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54454 Tue 27 Feb 2024 13:59:20 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51997 Tue 26 Sep 2023 11:07:44 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47747 Tue 21 Mar 2023 19:00:49 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45683 3 months ago, who had completed formal rehabilitation and had no significant cognitive impairment. Experimental group received botulinum toxin-A plus evidence-based movement training while the control group received botulinum toxin-A plus a handout of exercises. Primary outcomes were goal attainment (Goal Attainment Scaling) and upper limb activity (Box and Block Test) at 3 months (end of intervention). Secondary outcomes were spasticity, range of motion, strength, pain, burden of care, and health-related quality of life. Results: In terms of goal attainment, the experimental group scored the same (mean difference, 2 T-score [95% CI, −2 to 7]) as the control group on the Goal Attainment Scale. In terms of upper limb activity, by 3 months the experimental group moved blocks at the same speed (mean difference, 0.00 blocks/s [95% CI, −0.02 to 0.01]) as the control group on the Box and Block Test. There were no differences between groups on any secondary outcome except strength, in favor of the experimental group (mean difference, 1.4 kg [95% CI, 0.2–2.7]). Conclusions: Findings suggest that additional intensive upper limb rehabilitation following botulinum toxin-A in chronic stroke survivors with a disabled upper limb is not effective. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: ACTRN12615000616572. (Stroke. 2020;51:556-562. DOI: 10.1161/STROKEAHA.119.027602.)]]> Tue 21 Mar 2023 17:56:38 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43470 4 months (75% mepolizumab; 25% omalizumab, and 25% macrolide) were recruited. Qualitative semi structured interviews were conducted, with interviews thematically analysed. Results: Participants’ mean (SD) age was 59.5 (15.3) years, and 50% were male. Participants reported 4.5 (2.3) exacerbations in the past year. Asthma Control Questionnaire score was 2.0 (1.4). The monoclonal add-on therapies had been prescribed for a median (IQR) of 12.5 (7.0, 24.0) months. Experience was captured in four emergent themes: “Life is just easier” provided an overall message that the add-on therapy made the participants’ life easier in terms of increasing participation, levelling out symptoms, providing more energy and reducing healthcare use. “Prednisone: A necessary evil” was discussed, particularly in terms of dose and dependence and damaging side effects. The theme “worry and hope for the future” referenced treatment non-response or cessation of effect which was discussed by some participants. Finally, “holistic care” was centred on the sentiment that the participant’s asthma management and overall health were not related to one aspect or medication alone. Conclusion: Patients with severe asthma experience vast improvements in quality-of-life and life participation with add-on therapies, but there remains a significant burden related to oral corticosteroids and incomplete treatment responses. Addressing this residual burden is an important area for future research.]]> Tue 20 Sep 2022 10:13:32 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40883 Tue 19 Jul 2022 14:52:21 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41961 Tue 16 Aug 2022 14:45:44 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41935 Tue 16 Aug 2022 10:26:25 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46335 r = 0.38; p < .0005). Mean clinician estimates were higher than patient reported utility (0.60 vs 0.54; p = 0.008), with significant underestimation of reported problems apparent in three of the five EQ-5D-5L domains. Patient sex (female), depressed mood and frailty were all associated with an increased inter-rater gap.Conclusion: Clinicians in this sample overestimated HRQoL. Factors affecting the inter-rater gap, including sex and depression, support formal HRQoL screening to enhance clinical conversations and decision making. The discrepancy also supports regulatory restriction on the use of expert opinion in the development of QALYs in health economic analysis.]]> Tue 15 Nov 2022 12:55:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51613 Tue 12 Sep 2023 13:49:03 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51598 Tue 12 Sep 2023 12:25:08 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55620 Tue 11 Jun 2024 14:46:44 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55571 Tue 11 Jun 2024 10:27:03 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36564 Tue 09 Jun 2020 13:09:47 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34934 Thu 28 Oct 2021 12:36:04 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45193 Thu 27 Oct 2022 14:56:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35695 Thu 27 Jan 2022 15:56:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42577 Thu 25 Aug 2022 14:35:16 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37041 Thu 24 Mar 2022 11:31:27 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51191 Thu 24 Aug 2023 14:38:33 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39023 Thu 21 Apr 2022 09:51:00 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48885 10 years: 65% vs. 33%, p < 0.002). QoL was impaired in both groups, but there were no significant differences between severe asthma and COPD carers in either of the SF-12 component scores. The HADS scores revealed no difference between groups. Compared to severe asthma carers, COPD carers had significantly greater needs for: ‘having time for self’ (33% vs. 13%, p = 0.006), ‘equipment to help care for relative’ (33% vs. 13%, p = 0.006), ‘practical help in the home’ (35% vs. 18%, p = 0.006) and ‘getting a break from caring overnight’ (21% vs. 6%, p = 0.023). Conclusion: QoL is impaired in carers of people with severe asthma to a similar degree of COPD carers and other debilitating diseases like cancer. These novel data highlight the support needs of severe asthma carers and identifies areas where tailored support is needed to reduce their substantial carer burden.]]> Thu 20 Apr 2023 09:27:47 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37386 80 nmol/L. The primary objectives were to assess the effect of supplementation on renal-specific symptoms and on hand-grip strength. Symptoms were assessed using the Kidney Disease Quality of Life Short Form and muscle strength with a hand grip-strength dynamometer. Hypothesis testing was by two-group t-test and Wilcoxon rank-sum on an intention-to-treat basis. Results: In all, 68 participants were randomized and received study medication. Median 12-month plasma 25(OH)D concentration was 119 nmol/L and 37 nmol/L in the cholecalciferol and placebo groups, respectively. There was no statistical difference in primary outcomes at 12 months. Mean symptom scores at 12 months were two lower in the cholecalciferol group (95% confidence interval −10 to 6) and geometric mean grip-strength was 27 kg in both groups. Symptoms, strength, BP, plasma mineral bone parameters and adverse events were not different between the groups at follow-up. Conclusions: High-dose cholecalciferol in a deficient dialysis population had no effect on muscle strength or symptoms but appears safe.]]> Thu 17 Feb 2022 09:30:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36206 Thu 17 Feb 2022 09:29:46 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38922 Thu 16 Nov 2023 12:20:26 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48863 Thu 13 Apr 2023 13:01:42 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47317 Thu 06 Jul 2023 13:59:45 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36103 0.5) standardized loadings on their respective latent variables and all reached statistical significance (P<0.0001), supporting their relationships with the hypothesized domains. Convergent validity was strongly supported, with every domain being correlated with multiple external instruments; the majority of correlations were in the range 0.3-0.5 (in absolute values). The items comprising each domain showed good internal consistency, with the lowest value of Chronbach α at 0.80. Scores based on the short form (10-item) version of the NDI correlated strongly with the full 25-item form (tension ρ=0.88, interference ρ=0.94, eat/drink ρ=0.95, knowledge ρ=0.84 and work/study ρ=0.97; all P<0.0001). Conclusion: The NDI is a valid instrument that can be used to measure the disease-specific impact of FD on quality of life.]]> Thu 06 Feb 2020 13:08:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49063 Thu 04 May 2023 08:07:12 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46842 Thu 01 Dec 2022 16:04:34 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52861 100, one contributing to meta‐analysis), mean age range 27 to 54 years). We identified one ongoing study and three studies awaiting classification. One study was synthesised narratively, and another involved participants specifically with asthma‐COPD overlap. Most programmes were outpatient‐based, lasting from three to four weeks (inpatient) or eight to 12 weeks (outpatient). Education or self‐management components included breathing retraining and relaxation, nutritional advice and psychological counselling. One programme was specifically tailored for people with severe asthma. Pulmonary rehabilitation compared to usual care may increase maximal oxygen uptake (VO2 max) after programme completion, but the evidence is very uncertain for data derived using mL/kg/min (MD between groups of 3.63 mL/kg/min, 95% confidence interval (CI) 1.48 to 5.77; 3 studies; n = 129) and uncertain for data derived from % predicted VO2 max (MD 14.88%, 95% CI 9.66 to 20.1%; 2 studies; n = 60). The evidence is very uncertain about the effects of pulmonary rehabilitation compared to usual care on incremental shuttle walk test distance (MD between groups 74.0 metres, 95% CI 26.4 to 121.4; 1 study; n = 30). Pulmonary rehabilitation may have little to no effect on VO2 max at longer‐term follow up (9 to 12 months), but the evidence is very uncertain (MD −0.69 mL/kg/min, 95% CI −4.79 to 3.42; I2 = 49%; 3 studies; n = 66). Pulmonary rehabilitation likely improves functional exercise capacity as measured by 6‐minute walk distance, with MD between groups after programme completion of 79.8 metres (95% CI 66.5 to 93.1; 5 studies; n = 529; moderate certainty evidence). This magnitude of mean change exceeds the minimally clinically important difference (MCID) threshold for people with chronic respiratory disease. The evidence is very uncertain about the longer‐term effects one year after pulmonary rehabilitation for this outcome (MD 52.29 metres, 95% CI 0.7 to 103.88; 2 studies; n = 42). Pulmonary rehabilitation may result in a small improvement in asthma control compared to usual care as measured by Asthma Control Questionnaire (ACQ), with an MD between groups of −0.46 (95% CI −0.76 to −0.17; 2 studies; n = 93; low certainty evidence); however, data derived from the Asthma Control Test were very uncertain (MD between groups 3.34, 95% CI −2.32 to 9.01; 2 studies; n = 442). The ACQ finding approximates the MCID of 0.5 points. Pulmonary rehabilitation results in little to no difference in asthma control as measured by ACQ at nine to 12 months follow‐up (MD 0.09, 95% CI −0.35 to 0.53; 2 studies; n = 48; low certainty evidence). Pulmonary rehabilitation likely results in a large improvement in quality of life as assessed by the St George's Respiratory Questionnaire (SGRQ) total score (MD −18.51, 95% CI −20.77 to −16.25; 2 studies; n = 440; moderate certainty evidence), with this magnitude of change exceeding the MCID. However, pulmonary rehabilitation may have little to no effect on Asthma Quality of Life Questionnaire (AQLQ) total scores, with the evidence being very uncertain (MD 0.87, 95% CI −0.13 to 1.86; 2 studies; n = 442). Longer‐term follow‐up data suggested improvements in quality of life may occur as measured by SGRQ (MD −13.4, 95% CI −15.93 to −10.88; 2 studies; n = 430) but not AQLQ (MD 0.58, 95% CI −0.23 to 1.38; 2 studies; n = 435); however, the evidence is very uncertain. One study reported no difference between groups in the proportion of participants who experienced an asthma exacerbation during the intervention period. Data from one study suggest adverse events attributable to the intervention are rare. Overall risk of bias was most commonly impacted by performance bias attributed to a lack of participant blinding to knowledge of the intervention. This is inherently challenging to overcome in rehabilitation studies. Authors' conclusions: Moderate certainty evidence shows that pulmonary rehabilitation is probably associated with clinically meaningful improvements in functional exercise capacity and quality of life upon programme completion in adults with asthma. The certainty of evidence relating to maximal exercise capacity was very low to low. Pulmonary rehabilitation appears to confer minimal effect on asthma control, although the certainty of evidence is very low to low. Unclear reporting of study methods and small sample sizes limits our certainty in the overall body of evidence, whilst heterogenous study designs and interventions likely contribute to inconsistent findings across clinical outcomes and studies. There remains considerable scope for future research.]]> Mon 30 Oct 2023 10:01:13 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46624 unadjusted 1 year, -0.147; 95% CI, -0.258 to -0.036; 5 years, -0.090; 95% CI, -0.119 to -0.062). After adjustment for age, stroke severity, prestroke dependency, and depression, these pooled median differences were attenuated, more greatly at 1 year (-0.067; 95% CI, -0.111 to -0.022) than at 5 years (-0.085; 95% CI, -0.135 to -0.034). Conclusions: Women consistently exhibited poorer HRQoL after stroke than men. This was partly attributable to women's advanced age, more severe strokes, prestroke dependency, and poststroke depression, suggesting targets to reduce the differences. There was some evidence of residual differences in HRQoL between sexes but they were small and unlikely to be clinically significant.]]> Mon 28 Nov 2022 11:32:40 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44765 Mon 24 Oct 2022 08:49:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50387 75 % of participant agreement. Results: The consensus DOOR comprised four main dimensions. The primary dimension was patient-reported joint function. The secondary dimensions were infection cure and mortality. The final dimension of quality of life was selected as a tie-breaker. Discussion: A desirability of outcome ranking for periprosthetic joint infection has been proposed. It focuses on patient-centric outcome measures of joint function, cure and quality of life. This DOOR provides a multidimensional assessment to comprehensively rank outcomes when comparing treatments for prosthetic joint infection.]]> Mon 24 Jul 2023 14:12:35 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34366 Mon 23 Sep 2019 12:03:38 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42396 Mon 22 Aug 2022 16:00:23 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48509 2 with filgrastim support every 3 weeks for 3 cycles (HDEC) or standard dose epirubicin 75 mg/m² and cyclophosphamide 750 mg/m² every 3 weeks for 6 cycles (SDEC). Primary outcomes were time to progression, overall survival and quality of life. Results: In 118 patients allocated HDEC 90% of the planned dose was delivered, compared to 96% in the 117 participants allocated SDEC. There were no significant differences in the time to disease progression (5.7 vs. 5.8 months, P = 0.19) or overall survival (14.5 vs. 16.5 months, P = 0.29) between HDEC and SDEC, respectively. Patients on HDEC reported worse quality of life during therapy, but scores improved after completion to approximate those reported by patients allocated SDEC. Objective tumour response was recorded in 33 (28%) on HDEC and 42 patients (36%) on SDEC. HDEC produced more haematologic toxicity. Conclusion: For women with metastatic breast cancer, disease progression, survival or quality of life were no better with high-dose intensity compared to standard dose EC chemotherapy. Australian Clinical Trials Registry registration number ACTRN12605000478617.]]> Mon 20 Mar 2023 16:24:14 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49437 Mon 15 May 2023 13:51:09 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53789 70 years) had not returned to their pre-hospital residence. Conclusion: Patients who survive 90 and 365 days following EL nearly all return to their pre-hospital residence, with only a very small proportion of previously independent patients entering dependent care. This should help inform shared decision-making regarding emergency laparotomy in the acute setting.]]> Mon 15 Jan 2024 10:45:24 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46241 N = 1432 women diagnosed with AF from 2000 to 2015 of the old cohort (born 1921–26) of the Australian Longitudinal Study on Women’s Health (ALSWH) who remained alive for at least 12 months post first recorded AF diagnosis. Self-reported data on demographics, health behaviours, health conditions, and SF-36 were obtained from the ALSWH surveys, corresponding to within three years of the date of the first record of AF diagnosis. Linked Pharmaceutical Benefits Scheme (PBS) data determined the use of oral anticoagulants and comorbid conditions, included in CHA₂DS₂-VA (Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes, Stroke or TIA, Vascular disease and Age 65–74 years) score calculation, were assessed using state-based hospital admissions data. Utility scores were calculated for every woman from their SF-36 responses using the SF-6D algorithm with Australian population norms. Mean utility scores were then calculated for women with various demographic, health behaviours, and clinical characteristics. Ordinary Least Square (OLS) regression modelling was performed to determine factors associated with these utility scores. Two different scenarios were used for the analysis: (1) complete-case, for women with complete data on all the SF-36 items required to estimate SF-6D (N = 584 women), and (2) Multiple Imputation (MI) for missing data, applied to missing values on SF-36 items (N = 1432 women). MI scenario was included to gauge the potential bias when using complete data only. Results: The mean health utility was estimated to be 0.638 ± 0.119 for the complete dataset and 0.642 ± 0.120 for the dataset where missing values were handled using MI. Using the MI technique, living in regional and remote areas (β=0.016±0.007) and the use of oral anticoagulants (β=0.021±0.007) were positively associated with health utility compared to living in major cities and no use of anticoagulants, respectively. Difficulty to manage on available income (β=−0.027±0.009), no/low physical activity (β=−0.069±0.011), disability (β=−0.097±0.008), history of stroke (β=−0.025±0.013) and history of arthritis (β=−0.024±0.007) were negatively associated with health utility. Conclusion: This study presents health utility estimates for older women with AF. These estimates can be used in future clinical and economic research. The study also highlights better health utilities for women living in regional and remote areas, which requires further exploration.]]> Mon 14 Nov 2022 13:17:50 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54725 Mon 11 Mar 2024 14:12:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44178 Mon 10 Oct 2022 10:20:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50230 Mon 10 Jul 2023 14:00:54 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52345 The purpose of this study was to evaluate the effect of custom-made orthotics on pain, health-related quality of life (HRQoL), function and fatigue in children and adolescents with generalised joint hypermobility (GJH) and lower limb pain. Fifty-three children aged 5–18 years were fitted with custom-made polypropylene orthotics. Visual analogue scale (VAS) assessed lower limb pain severity, Paediatric Quality of Life Inventory assessed HRQoL and fatigue and six-minute walk test (6 MWT) measured functional endurance at baseline, at 1 month and 3 months post-intervention. A mixed model including a random intercept for participant and a fixed effect for time was used to assess differences in outcomes over time. Fifty-two children completed the study (mean age 10.6-years). Children reported significantly reduced pain (mean VAS reduction −27/100, 95%CI: −33, −21), improved HRQoL (mean total improvement 11/100, 95%CI: 7, −15), functional capacity (mean 6MWT improvement 27 m, 95%CI: 18, −36) and fatigue (mean total improvement 13/100, 95%CI: 9, −17) after 1 month of wearing the custom-made orthotics. From 1 month to 3 months there was further statistically but not clinically significant reduction in pain while benefit on other outcomes was maintained. In this study, children with GJH reported reduced lower limb pain, improved HRQoL, functional endurance and fatigue after a month post-fitting of custom-made orthotics which was maintained over a 3 month period. Orthotics were well-tolerated with no serious adverse events reported.]]> Mon 09 Oct 2023 14:57:37 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41496 Mon 08 Aug 2022 10:55:52 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50755 Mon 07 Aug 2023 15:25:43 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54598 Mon 04 Mar 2024 08:42:34 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38064 SD = 14.6). Of the participants, 83% had two chronic conditions. Participants reported impaired physical and mental QoL when compared with the general population in China. Poorer QoL was correlated with stronger illness perceptions of consequences and timeline and increased use of denial and disengagement and self-blame. Increasing age and more chronic conditions were associated with worse QoL. A higher education level was significantly associated with better physical and mental QoL. Conclusions: This study found that adults with MCCs living in China experienced impaired QoL. The strong relationship found between the participants' perceptions of MCCs, coping strategies, and QoL suggested that healthcare professionals should recognize the physical and psychological impacts of MCCs and address the significance of adaptations to MCCs in future treatment programs. The findings will help healthcare professionals design more specific interventions to modify illness perceptions and enhance certain coping strategies to improve the QoL of people with MCCs. Healthcare professionals can mobilize available resources from healthcare and social systems to enhance people's coping and adaptation to MCCs. Clinical Relevance: With an understanding of the illness perceptions of people with MCCs, healthcare professionals could offer information related to consequences, timeline, and personal control to enable better alignment between people's expectations and their actual situations. By knowing people's coping strategies, healthcare professionals can offer additional support to people who prefer strategies of denial and disengagement and self-blame.]]> Mon 02 Aug 2021 09:59:46 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38060 Mon 02 Aug 2021 08:43:10 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43798 1 site), and one third had ≥5 joint pain sites. Compared to women with fewer joint pain sites, women with >5 joint pain sites (multisite joint pain) had significantly poorer physical and emotional health-related quality of life, more severe pain, a higher probability of neuropathic pain, and a longer duration of pain. More than half of women in the multisite joint pain group were still employed, statistically significantly more than women with no joint pain. In the final model, pain duration, the number of medications, pain intensity (discomforting and distressing) and the physical component of health-related quality of life were significantly associated with increased number of joint pain sites. Conclusions: Over one-third of older women in our sample had >5 painful joints in the last month. These women demonstrated significantly poorer psychosocial health, and increased medication use, than women with no or fewer sites of joint pain. Many women with multisite joint pain were still in the workforce, even when nearing retirement age. This study has important implications for future research into musculoskeletal pain, particularly in regards to womens health and wellbeing, and for clinical practice where there should be increased awareness of the implications of concurrent, multisite joint pain.]]> Fri 30 Sep 2022 14:15:32 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38832 Fri 25 Nov 2022 10:23:23 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55398 Fri 24 May 2024 11:36:24 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52691 Fri 20 Oct 2023 15:54:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38399 Fri 17 Dec 2021 11:17:46 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49944 Fri 16 Jun 2023 11:15:41 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47245 Fri 16 Dec 2022 12:22:32 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54824 Fri 15 Mar 2024 09:11:39 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39974 n=409). We find that less than half of the participants worry about crime but that a sizable minority (13%) indicated that they have some worry about a category of crime every week of the year or more. Building on a recent conceptual advance Gray et al. 2011), we differentiate between functional and dysfunctional fear of crime. We find that greater direct and indirect experience of victimization, believing one's neighbourhood to be disorderly, and believing that collective efficacy is low all predict moving up the scale from no worry, to functional fear, to increasingly frequent dysfunctional fear. The findings suggest gender and age are largely unrelated to worry about crime, controlling for perceptions of community disorder, perceptions of collective efficacy, direct victimisation experience and indirect victimisation experience. We conclude with some thoughts on the role of environmental cues in shifting people's functional response to perceived risk to dysfunctional patterning of emotions in people's daily lives.]]> Fri 15 Jul 2022 10:18:18 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49364 Fri 12 May 2023 12:42:06 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38376 Fri 10 Sep 2021 10:31:31 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39508 Fri 10 Jun 2022 15:14:28 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51535 Fri 08 Sep 2023 12:31:27 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54696 Fri 08 Mar 2024 12:07:07 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45712 Fri 04 Nov 2022 10:23:59 AEDT ]]>